RetroVascular Acquisition to Obtain Plasma Energy Technology and Advance CTO Treatment
First written in FY2018. 5 of 8 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025SoftenedAnnual report
「The Plasma Wire System, which we had been developing for many years as a next-generation CTO penetration device in the cardiovascular field, completed an exploratory clinical trial last year and was being prepared for a confirmatory clinical trial, but we abandoned its development for business reasons.」
The Company abandoned development of the plasma wire system under its previous plan to apply ASAHI Medical Technologies’ plasma technology to CTO treatment. It continues to explore other applications for the technology. - FY2024RestatedAnnual report
「As a research and development-oriented company, we will continue to develop products incorporating new functions based on advanced technologies, such as plasma guidewires for cardiovascular and peripheral vascular applications and Stroke Smart Guidewires for cerebrovascular applications, thereby contributing to the wider adoption and advancement of minimally invasive treatment.」
The Company continues to pursue its policy of developing products using advanced technologies, including plasma guidewires and Stroke Smart Guidewires. - FY2021RestatedAnnual report
「The plasma technology has already been established, and we are setting milestones for clinical trials, regulatory applications and approvals toward commercialization.」
The Company continues to monitor progress on clinical trials, regulatory applications and approvals to commercialize ASAHI Medical Technologies’ plasma technology and apply it to CTO treatment. - FY2019RestatedAnnual report
「Going forward, we believe that integrating AMT’s plasma-energy technology with the technologies held by our Group will enable us to develop innovative medical devices that improve treatment outcomes in the CTO field, thereby accelerating the shift from surgical procedures to PTCA treatment in the CTO field.」
The Company continues to pursue its objective of advancing CTO treatment by integrating the plasma-energy technology of ASAHI Medical Technologies, formerly RetroVascular, with its proprietary technologies. - FY2019-Q3RestatedAnnual report
「ASAHI INTECC USA, INC., a consolidated subsidiary of the Company, acquired the shares of RetroVascular, Inc. on 6 July 2018 and made it a subsidiary of the Company, specifically a second-tier subsidiary. The company changed its corporate name to ASAHI Medical Technologies, Inc. on 6 December 2018.」
The acquisition and conversion of RetroVascular, Inc. into a subsidiary, as well as the change in corporate name to ASAHI Medical Technologies, Inc. on 6 December 2018, have been reconfirmed. - FY2019-Q2Reflects the change in corporate name following the acquisitionAnnual report
「ASAHI INTECC USA, INC., a consolidated subsidiary of the Company, acquired the shares of RetroVascular, Inc. on 6 July 2018 and made it a subsidiary of the Company, specifically a second-tier subsidiary. The company changed its corporate name to ASAHI Medical Technologies, Inc. on 6 December 2018.」
The acquisition and conversion of RetroVascular, Inc. into a subsidiary have been reconfirmed, together with the change in corporate name to ASAHI Medical Technologies, Inc. on 6 December 2018. - FY2019-Q1RestatedAnnual report
「As RetroVascular, Inc.’s shares were acquired during the first quarter of the consolidated fiscal year, the company has been included in the scope of consolidation.」
Following the acquisition of RetroVascular, the company was included in the scope of consolidation. The acquisition objective of advancing CTO treatment through the integration of plasma-energy technology with the Company’s technologies remains unchanged. - FY2018First statedAnnual report
「By integrating RetroVascular’s plasma-energy technology with the technologies held by our Group, we believe it will be possible to develop innovative medical devices that improve treatment outcomes in the CTO field, thereby accelerating the shift from surgical procedures to PTCA treatment in the CTO field.」
On 6 July 2018, the Company completed the acquisition of a 99.4% stake in RetroVascular, Inc. through ASAHI INTECC USA. This was initially presented as a measure intended to integrate plasma-energy technology with existing technologies, apply it to the CTO and peripheral vascular fields, and utilize an information-gathering base in Silicon Valley, United States.